This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Aegerion discloses tentative deal on drug marketing, but not on FCPA probe

( May 16, 2016, 21:35 GMT | Official Statement) -- MLex Summary: Aegerion Pharamaceuticals, based in Massachusetts, said in a securities filing that it has reached a preliminary agreement with US authorities to resolve a drug marketing case with guilty pleas to two misdemeanors and a five-year deferred prosecution agrement.  However, the company said that a probe by the US Department of Justice and the Securities and Exchange Commission over possible Foreign Corrupt Practices Act violations in Brazil has not been resolved.Excerpt:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections